In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 376 to 388 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]	Technology appraisal guidance	29 April 2026
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]	Technology appraisal guidance	TBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]	Technology appraisal guidance	22 November 2017
Women's and reproductive health guidelines	NICE guideline	TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]	Technology appraisal guidance	TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]	Technology appraisal guidance	TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	TBC
Zio XT for detecting cardiac arrhythmias	Medical technologies guidance	TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]	Technology appraisal guidance	TBC
Zuranolone for treating postnatal depression [ID6431]	Technology appraisal guidance	TBC

Results per page

10
25
50
All